Anti-Mouse CD8 [Clone YTS-169] — Purified in vivo PLATINUM™ Functional Grade

Anti-Mouse CD8 [Clone YTS-169] — Purified in vivo PLATINUM™ Functional Grade

Product No.: C2850

[product_table name="All Top" skus="C2850"]

- -
- -
Clone
YTS-169
Target
CD8
Formats AvailableView All
Product Type
Monoclonal Antibody
Isotype
Rat IgG2b κ
Applications
Depletion
,
FC
,
IHC FF
,
in vivo
,
WB

- -
- -
Select Product Size
- -
- -

Antibody Details

Product Details

Reactive Species
Mouse
Host Species
Rat
Recommended Isotype Controls
Recommended Dilution Buffer
Immunogen
CBA mouse thymocytes
Product Concentration
≥ 5.0 mg/ml
Endotoxin Level
<0.5 EU/mg as determined by the LAL method
Purity
≥98% monomer by analytical SEC
>95% by SDS Page
Formulation
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.
Product Preparation
Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.
Pathogen Testing
To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.
Storage and Handling
Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.
Country of Origin
USA
Shipping
Next Day 2-8°C
Applications and Recommended Usage?
Quality Tested by Leinco
FC The suggested concentration for this YTS-169 antibody for staining cells in flow cytometry is ≤ 0.2 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
WB The suggested concentration for this YTS-169 antibody for use in western blotting is 1-10 μg/ml.
Additional Applications Reported In Literature ?
IHC (Frozen)
Depletion
Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change.

Description

Description

Specificity
Clone YTS-169 recognizes mouse CD8.
Background
CD8 is made up of disulfide-linked α and β chains that form the α(CD8a)/β(CD8b) heterodimer and α/α homodimer. CD8 is part of the Ig superfamily that expresses primarily as CD8a homodimers. CD8a is a 32-34 kD type I glycoprotein that can also form heterodimers with CD8b. CD8 is an antigen co-receptor on T cells that mediates efficient cell to cell interactions within the immune system. CD8 coupled with the T cell receptor on the T lymphocyte recognizes an antigen displayed by an antigen presenting cell (APC) in the context of class I MHC molecules. The CD8 co-receptor also plays a role in T cell signaling by interacting with Lck (lymphocyte-specific protein tyrosine kinase) which leads to the activation of transcription factors that affect the expression of certain genes.
Antigen Distribution
CD8 is expressed on blood lymphocytes, a subset of NK cells, and thymocytes. Persons with HIV exhibit increased levels of CD8+ lymphocytes.
Ligand/Receptor
MHC class I molecule
PubMed
Research Area
Immunology

Leinco Antibody Advisor

Powered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments.

The most common in vivo application of clone YTS-169 in mice is the selective depletion of CD8⁺ T cells, primarily cytotoxic T lymphocytes, to study immune responses or model immune modulation.

Key in vivo uses include:

  • CD8⁺ T cell depletion: YTS-169 is consistently used to remove CD8⁺ cells by systemic injection, allowing researchers to study immune function without cytotoxic T cells or to model conditions (e.g., tumor immunology, autoimmune disease, infectious disease) where CD8⁺ T cells play a critical role.
  • Immune function studies: By depleting CD8⁺ T cells, investigators can assess the contribution of these cells to immune responses against infections, tumors, or during immunotherapy.
  • Blocking studies: Sometimes used to block CD8 interactions (such as with MHC I) to analyze the mechanistic role of CD8 engagement in T cell activation or signaling.
  • Combination with other antibodies: Frequently used alongside anti-CD4 depletion (e.g., clone GK1.5) to dissect the roles of different T cell subsets in vivo.

Additional applications sometimes reported (less common than depletion studies):

  • Preclinical models of transplantation, autoimmune disease, and cancer immunotherapy, where selective removal of CD8⁺ T cells is informative about disease mechanisms or therapeutic effects.
  • Functional blocking or labeling in flow cytometry or immunohistochemistry, though for strictly in vivo functional manipulation, depletion is predominant.

In summary, CD8⁺ T cell depletion is the principal in vivo application of clone YTS-169 in mouse models. This enables mechanistic studies of immune responses where the absence of cytotoxic T cells is informative.

Commonly used antibodies or proteins paired with YTS-169 (anti-mouse CD8α) in the literature include anti-CD4 antibodies and other CD8 antibodies, especially for distinguishing T cell subsets or for conducting immune cell depletion experiments.

Key details and common use cases:

  • Anti-CD4 antibodies (e.g., clone GK1.5): Frequently used in combination with YTS-169 for flow cytometric identification and depletion of CD4⁺ versus CD8⁺ T cell populations. Anti-CD4 antibodies are often conjugated with PE (phycoerythrin), and YTS-169 with FITC, to allow dual labeling of T cell subsets.
  • Other anti-CD8 antibodies (e.g., clone 2.43): Sometimes used alongside YTS-169 for differential staining or depletion, especially as 2.43 is specific for the Lyt2.2 allele, while YTS-169 binds both Lyt2.1 and Lyt2.2.
  • YTS-156 (anti-mouse CD8β): Occasionally used in depletion protocols in combination with YTS-169 to broadly ablate CD8⁺ T cells.

Additional proteins/antibodies sometimes co-used:

  • Recombinant mouse CD8αβ heterodimer proteins: Employed in vitro to confirm specificity and affinity of YTS-169 and related antibodies in biochemical assays.
  • Fluorochrome-conjugated versions: YTS-169 and other antibodies are widely available conjugated to various fluorochromes for multicolor flow cytometry, enabling combination with antibodies against CD3, CD4, CD44, CD62L, and other cell surface proteins depending on the panel.

Summary table:

Antibody/ProteinTargetCommon Use with YTS-169
GK1.5 (anti-CD4)Mouse CD4Depletion and subset identification
2.43 (anti-CD8α, Lyt2.2)Mouse CD8α (Lyt2.2)Subset discrimination, depletion controls
YTS-156Mouse CD8βDepletion with YTS-169
Recombinant CD8αβ proteinsMouse CD8αβ dimerSpecificity/affinity testing

In summary, anti-CD4 antibodies (often clone GK1.5) are the most common co-used reagent with YTS-169, with other anti-CD8 antibodies and recombinant proteins used for more specialized applications.

Clone YTS-169 (also cited as YTS169.4) is a rat monoclonal antibody widely used in scientific literature for identifying, depleting, and analyzing mouse CD8+ T cells in vivo and in vitro. Its use is fundamental in immunology, particularly in studies probing T cell function, immune cell depletion, and the role of CD8+ T cells in disease models.

Key findings from scientific literature citing clone YTS-169 include:

  • Reliable CD8+ T cell depletion: YTS-169 is extensively cited for its ability to selectively deplete CD8+ T cells in mice, which is a standard approach to study the function of these cells in immune responses, tumor immunity, and autoimmunity. This clone is considered gold-standard for such depletion studies due to its specificity and efficacy.

  • Specificity for mouse CD8α antigen: YTS-169 targets the CD8α chain, which is expressed on cytotoxic T cells and some subsets of other immune cells. It is widely used for flow cytometry, immunohistochemistry on frozen sections, and in vivo cell depletion.

  • Functional studies in models of disease: Research using YTS-169 has shown that depletion of CD8+ T cells with this clone abrogates certain forms of acquired immunity and is essential for dissecting the respective contributions of CD8+ versus CD4+ T cells in various disease models, including infections, cancer, and autoimmunity.

  • Instrumental in studies of immune memory: Depletion using YTS-169 demonstrated that the absence of CD8+ T cells can abolish memory responses in models of acquired immunity, underscoring the critical role of CD8+ T cells in long-term protection.

  • Optimization and limitations in usage: YTS-169 (YTS169.4) is often recommended for use in flow cytometry at less than or equal to 0.2 μg per 10^6 cells, and for immunohistochemistry on frozen tissues but not on paraffin-embedded samples. It is not generally useful for standard western blotting or immunohistochemistry on formalin-fixed, paraffin-embedded tissue.

  • Preferred tool in experimental immunology: Literature reviews and product pages note that YTS-169 is cited in over 95 publications, reflecting its status as a reference antibody for murine CD8α studies.

Summary of core uses of YTS-169 citations:

ApplicationFinding/Use
Depletion studiesSelective and effective removal of mouse CD8+ T cells in vivo
Immunophenotyping (Flow Cytometry)Accurate labeling of CD8+ T cells in murine samples
Functional characterizationDissecting CD8+ T cell roles in immunity and disease models
Antigen specificityRecognizes murine CD8α, not suitable for all species or tissues

In summary, clone YTS-169 and YTS169.4 are fundamental in CD8+ T cell research, enabling cell depletion, detection, and immuno-functional studies in mice across diverse fields such as oncology, autoimmunity, and virology, with usage and limitations well documented in the literature.

Dosing regimens for clone YTS-169 in mouse models demonstrate considerable variability based on experimental objectives, mouse strain characteristics, disease model complexity, and the desired extent and duration of CD8+ T cell depletion.

Standard Dosing Parameters

The typical dosing protocol for clone YTS-169 involves administering 200–400 µg per mouse every 3–7 days through intraperitoneal (i.p.) or intravenous (i.v.) injection. This protocol closely mirrors established standards for other anti-CD8 clones like 2.43, which commonly use doses ranging from 100 µg to 500 µg per mouse. However, dosing for YTS-169 can extend from the low hundreds of micrograms up to 1 mg per mouse per dose depending on specific experimental requirements.

Frequency and Administration Routes

The dosing schedule typically follows a maintenance pattern where antibody is administered every 3 to 7 days to sustain effective CD8+ T cell depletion. Some protocols employ an initial higher loading dose followed by lower maintenance doses to balance depletion efficiency with safety considerations. The preferred routes of administration are intraperitoneal or intravenous injection, with each route potentially affecting the kinetics and efficiency of depletion.

Model-Specific Variations

One documented example demonstrates the flexibility of dosing schedules: in autoimmunity studies using sOVA/OT-I mice, researchers administered three doses of YTS169.4 on days 5, 7, and 9 after birth to delay disease onset. In tumor immunology studies, mice received 200 µg of anti-CD8α (clone YTS169.4) for investigating immune responses to tumor heterogeneity.

Factors Influencing Dosing Decisions

Several critical factors determine the optimal dosing regimen for any particular experiment. Mouse strain characteristics affect antibody pharmacokinetics and immune responsiveness. The specific disease model being studied influences both the timing and magnitude of depletion required. Experimental goals—whether seeking transient depletion for mechanistic studies or sustained depletion for therapeutic modeling—fundamentally shape dosing strategies. Finally, the desired duration of CD8+ T cell absence must be balanced against potential immunogenicity from repeated antibody administration.

The depleting activity of YTS 169.4 makes it highly effective for in vivo applications, but researchers must carefully titrate their specific protocols to achieve optimal results for their particular experimental context.

References & Citations

1. Parnes, J. R. et al. (1989) Adv. Immunol. 44:265
2. Reinherz, E. L. et al. (1980) J. Immunol. 124:1301
3. Fischer, A. et al. (1983) Immunology 48:177
4. Merkenschlanger, M. et al. (1988) Eur. J. Immunol. 18:1653
5. Leukocyte Typing: 3rd Workshop: Code No. 567; 4th Workshop: Code No. N31
Depletion
Flow Cytometry
IHC FF
in vivo Protocol
General Western Blot Protocol

Certificate of Analysis

Formats Available

- -
- -
Disclaimer AlertProducts are for research use only. Not for use in diagnostic or therapeutic procedures.